Optimizing bevacizumab exposure in atezolizumab-based therapy for unresectable hepatocellular carcinoma: A nationwide real-world study

Hepatology

Long-term outcomes of atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: A real-world study

Hepatology

Tovoli F, Iavarone M, Cabibbo G, Marra F, Vivaldi C, Dalbeni A, Ponziani FR, Palloni A, Bergamo F, Rimassa L, Lani L, Federico P, Svegliati-Baroni G, Ielasi L, Mazzarelli C, De Lorenzo S, Sacco R, Bruccoleri M, Celsa C, Mastro A, Masi G, Auriemma A, Stella L, Toniutto P, Villani R, Lonardi S, Pressiani T, Piscaglia F, ARTE study group

doi: 10.1097/HEP.0000000000001725

Gastrointestinal Cancer

Transarterial Chemoembolization in Hepatocellular Carcinoma: Lessons from a 10-Year Real-World Retrospective Study

J Hepatocell Carcinoma

von Schoen-Angerer G, Pesola G, Garo ML, Marini G, Cappio S, Cerny A, Magenta L, Majno-Hurst P, Bernardi L, Cefalì M, Cristaudi A, Terziroli Beretta-Piccoli B, Trevisi E, De Dosso S

doi: 10.2147/JHC.S598858

Gastrointestinal Cancer

Determinants of long-term survival from atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma

Eur J Cancer

Lee PC, Cortellini A, Stefanini B, Yoo C, Chon HJ, Cheon J, Kudo M, Nishida N, Scheiner B, Pinter M, Lombardi P, Fulgenzi CAM, D'Alessio A, Brunetti L, Torkpour A, Valenzi E, Crowley F, Marron TU, Hsu WF, Celsa C, Cabibbo G, Cammà C, Galle PR, Vivaldi C, Masi G, Sharma R, Lin RP, Lin CY, Wietharn B, Saeed A, Tovoli F, Piscaglia F, Dalbeni A, Auriemma A, Sacerdoti D, Parisi A, Manfredi GF, Dondo A, Rimassa L, Pirisi M, Schönlein M, von Felden J, Singal AG, Parkih ND, Andanamala H, Ulahannan S, Roehlen N, Thimme R, Huang YH, Pinato DJ

doi: 10.1016/j.ejca.2026.116749

Gastrointestinal Cancer

Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced hepatocellular carcinoma (TALENTOP): a multicentre, open-label, randomised, phase 3 trial

Lancet

Sun HC, Zhu XD, Shen F, Song TQ, Bai XL, Zeng YY, Chen MS, Huang ZY, Cai JQ, Gao J, Kuang M, Li DY, Xing BC, Li XC, Wen TF, Peng T, Wang YD, Liu LX, Huang C, Shi YH, Huang XW, Wang K, Gao Q, Zhou J, Fan J

doi: 10.1016/S0140-6736(26)01252-3

Gastrointestinal Cancer

Clinical impact of extrahepatic metastatic patterns in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab

Eur J Cancer

Vo-Quang E, Campani C, Allaire M, Bouattour M, Regnault H, Marra F, Sutter O, Leroy V, Trepo E, Mouri S, Thabut D, Ozenne V, Sidali S, Hollande C, Boros C, Nahon P, Ganne-Carrié N, Lequoy M, Amaddeo G, Nault JC, Paris Liver Cancer Group

doi: 10.1016/j.ejca.2026.116704

Further Publications

Effectiveness and tolerability of bezafibrate in primary biliary cholangitis - a nationwide real-world study

Am J Gastroenterol

van Hooff MC, de Veer RC, Werner E, Beuers U, Drenth JPH, Cuperus FJC, van Hoek B, Veldt BJ, Klemt-Kropp M, van Meer S, Verdonk RC, Flink HJ, Vrolijk JM, Gevers TJG, Ponsioen CY, van Rooij JE, Kerbert-Dreteler MJ, Nicolaas JS, Marleen de Vree J, de Vries ES, Friederich PW, Tielemans MM, Aktas H, Hotho DM, de Wit U, Kuyvenhoven JPH, Abraham S, Kuiper EMM, Schmittgens S, Alderlieste YA, de Boer YS, Janssen HLA, Hansen BE, Erler NS, van der Meer AJ, Dutch PBC Cohort Study Group, Dutch PBC Cohort Study Group

doi: 10.14309/ajg.0000000000003879

Gastrointestinal Cancer

On-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab in patients with untreated hepatocellular carcinoma (TALENTACE): a multicentre, randomised, open-label, phase 3 trial

Lancet Gastroenterol Hepatol

Kudo M, Ogasawara S, Liu R, Gu S, Wang K, Zhao M, Hu H, Liu Z, Lin K, Liu J, Lin Z, Zhang Y, Peng T, Song J, Ueno M, Zhu J, Bai L, Tong L, Shi Y, Han G, Dong J

doi: 10.1016/S2468-1253(26)00212-8

Gastrointestinal CancerHepatology

Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma

J Hepatol

Yopp A, Chen M, Cheng AL, Kaseb A, Kudo M, Lee HC, Cha E, Hack SP, Lian Q, Spahn J, Wu C, Qin S, Chow PK

doi: 10.1016/j.jhep.2026.01.006

Inflammatory Bowel Disease

Treat-to-target optimization of biologic therapy is effective on endoscopic and histologic outcomes in a real-life cohort of ulcerative colitis-the TACTIC-UC study

J Crohns Colitis

Privitera G, Bezzio C, Buono AD, Gabbiadini R, Loy L, Ranucci L, Bertin L, Masoni B, Migliorisi G, Sauta E, Delleani M, Savevski V, Porta MD, D'amico S, Armuzzi A

doi: 10.1093/ecco-jcc/jjaf239

Related content

Long-term outcomes of atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: A real-world study

Transarterial Chemoembolization in Hepatocellular Carcinoma: Lessons from a 10-Year Real-World Retrospective Study

Determinants of long-term survival from atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma

Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced hepatocellular carcinoma (TALENTOP): a multicentre, open-label, randomised, phase 3 trial

Clinical impact of extrahepatic metastatic patterns in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab

Effectiveness and tolerability of bezafibrate in primary biliary cholangitis - a nationwide real-world study

On-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab in patients with untreated hepatocellular carcinoma (TALENTACE): a multicentre, randomised, open-label, phase 3 trial

Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma

Treat-to-target optimization of biologic therapy is effective on endoscopic and histologic outcomes in a real-life cohort of ulcerative colitis-the TACTIC-UC study